Matching the Mechanism to the Story: A Smaller Number for a Better-Fitting Drug
A woman with obesity, untreated depression, and eating she describes as stress- and boredom-driven rather than hunger-driven is offered naltrexone-bupropion over a more potent GLP-1 agonist — a choice built on mechanism fit, not the biggest topline weight-loss number.
Deborah H., a 39-year-old paralegal, described her relationship with food in terms her physician found more clinically useful than most patients offer unprompted: not hunger she couldn't satisfy, but a pull toward eating that showed up reliably at specific moments — the hour after a difficult deposition, the stretch of a slow afternoon with nothing due, the drive home after a fight with her partner. She's carried a diagnosis of mild-to-moderate depression for six years, never treated with medication, managed instead through therapy she describes as 'helpful but not enough,' and a BMI that has climbed from 29 to 33 over roughly that same span.
What she was actually asking for at today's visit wasn't a specific drug by name, the way many patients now arrive already requesting a GLP-1 agonist — she was asking whether there was something that addressed 'the actual reason I eat, not just how much I eat.' That framing turns out to matter pharmacologically, not just rhetorically: GLP-1 receptor agonists work primarily through satiety signaling, blunting hunger and slowing gastric emptying, a mechanism that doesn't directly target the situational, reward-driven eating pattern Deborah is describing. Naltrexone-bupropion works through a genuinely different pathway, combining opioid receptor blockade with dopamine-norepinephrine reuptake inhibition to act on the mesolimbic reward circuitry implicated in exactly this kind of cue-driven eating.
The complicating fact, and the reason this isn't a simple mechanism-matching exercise, is that naltrexone-bupropion's own pivotal COR-I and COR-II trials produced meaningfully smaller average weight loss than what GLP-1 agonists now routinely achieve — a real tradeoff between a drug that fits her described problem and one that has, in a more general population, produced a bigger number.
In clinic, matching a drug to a described pattern
I'd lead with naltrexone-bupropion here rather than a GLP-1 receptor agonist, and the reason is specific to her, not a general preference. She's described her eating in terms that map closely onto food-cue reactivity — strong, situational urges to eat in response to stress and boredom rather than physical hunger — and bupropion's dopaminergic and noradrenergic activity plus naltrexone's opioid-receptor blockade were designed around exactly that reward-pathway mechanism, distinct from the appetite-suppression-via-satiety-signaling that GLP-1 drugs work through.
There's a second reason bupropion specifically fits her: her depression has run mild-to-moderate and untreated for years, and bupropion carries a real antidepressant indication on its own, which a GLP-1 agonist doesn't.
I'd weigh in with one caution before we finalize that: naltrexone-bupropion's weight-loss magnitude in the COR-I and COR-II pivotal trials was meaningfully smaller than what GLP-1 receptor agonists now routinely produce — typically in the mid-single-digit-to-low-double-digit percent range, well under semaglutide or tirzepatide's own results. If her primary problem were framed purely as 'how much weight can we take off,' I'd lean the other way.
But her own description of the problem isn't primarily about appetite magnitude, it's about a specific behavioral trigger pattern, and a smaller topline weight-loss number attached to a drug that's actually mechanistically aimed at her stated problem may outperform a larger number attached to a drug that isn't.
Agreed, and I'd frame the choice to her exactly that way rather than let her compare topline trial percentages across drug classes as if they were measuring the same thing. If naltrexone-bupropion doesn't adequately address either the mood symptoms or the eating pattern within a few months, a GLP-1 agonist remains a real option to add or switch to — this isn't a one-shot decision that forecloses the more potent option if it turns out to be needed.
Agreed: start naltrexone-bupropion, titrated per label, alongside continued psychotherapy, with the choice explained to Deborah as a mechanism-first decision rather than a settling for a smaller number.
No real disagreement remained by the end of the visit; both physicians framed a future switch to or addition of a GLP-1 agonist as a genuine option if this approach doesn't adequately address her mood or eating pattern within a few months, not a door being closed today.